Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atara Biotherapeutics, Inc. following a significant stock price drop after the FDA's Complete Response Letter regarding its drug EBVALLO™ [1][3]. Group 1: Company Overview - Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapies for patients with serious diseases [1]. - The company’s stock experienced a dramatic decline of 56.99%, falling $7.79 to close at $5.88 per share on January 12, 2026, after the FDA's announcement [3]. Group 2: FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter (CRL) for its EBVALLO™ Biologics License Application (BLA) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease [3]. - The CRL indicated that the FDA could not approve the BLA in its current form, citing inadequacies in the evidence of effectiveness from the single arm ALLELE trial [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atara Biotherapeutics, following a significant stock price drop after the FDA's Complete Response Letter regarding its EBVALLO™ treatment [1][3]. Group 1: Company Overview - Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is under investigation for possible securities fraud or other unlawful business practices [1]. - The company recently faced a setback when the FDA issued a Complete Response Letter for its EBVALLO™ Biologics License Application, indicating that the application could not be approved in its current form [3]. Group 2: FDA Response and Impact - The FDA's Complete Response Letter stated that the single-arm ALLELE trial, previously deemed adequate for the BLA filing, is now considered insufficient for demonstrating effectiveness for accelerated approval [3]. - Following the FDA's announcement, Atara's stock price plummeted by $7.79 per share, a decrease of 56.99%, closing at $5.88 per share on January 12, 2026 [3].

Core Insights - Several companies have experienced significant price changes due to various underlying factors, including corporate developments, industry shifts, and broader economic conditions [5] Company-Specific Summaries - Atara Biotherapeutics, Inc. (Nasdaq: ATRA) saw its price drop by approximately 54% to $6.28, down from a year-high of $19.14, potentially due to concerns over trial results, regulatory hurdles, or financial sustainability, particularly after receiving a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for EBVALLO™ [1][6] - Nuvation Bio Inc. (NUVB-WT) experienced a nearly 47% decrease in price to $0.09, reflecting investor skepticism possibly due to challenges in its oncology-focused pipeline and a lack of recent positive news [2][6] - Lyra Therapeutics, Inc. (LYRA) witnessed a 46% drop in its price to $2.04, attributed to concerns over the clinical progress of its key product candidates or potential financial constraints impacting its research and development activities [3] - Mingteng International Corporation Inc. (Nasdaq: MTEN) saw its price fall by over 41% to $0.077, possibly related to operational challenges, market competition, or broader economic factors affecting the manufacturing sector, despite announcing an expansion of its strategic collaboration in the new energy vehicle sector [4]